Regeneron ends year on a high note

Date December 20, 2010

Hopes for a second indication for vision loss treatment VEGF Trap-Eye is the icing on the Christmas cake for Regeneron Pharmaceuticals. The earlier-than-anticipated pivotal data, showing a significant improvement in vision in patients with a form of macular oedema, comes only a month after similarly encouraging results in macular degeneration (Dosing the jewel in VEGF Trap-Eye’s crown, November 22, 2010).

Despite the good news, Regeneron shares were little changed today, albeit trading at a nine-and-a-half year high of $33. To ignite further excitement the company needs to deliver positive data on its second late-stage hope, aflibercept, which should start to emerge next year. And with only topline results revealed so far on VEGF Trap-Eye, further detail here will make for crucial reading. Regeneron is approaching a market value of $3bn; to breach this amount next year must bring more good news.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd